Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.32 |
| ▸ | PDE2A | O00408 | 2/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31269000 | 0.94 | PDE2A (0.39) | KCNH2SCN5ASCN9APIK3CDMCHR1 | |
| SCHEMBL31269467 | 0.93 | KCNH2 (0.34) | KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31268776 | 0.93 | KCNH2 (0.41) | KCNH2SCN5ASCN9APIK3CDCNR1 | |
| SCHEMBL31269028 | 0.89 | KCNH2 (0.37) | KCNH2SCN5ASCN9APIK3CDMCHR1 | |
| SCHEMBL31268997 | 0.89 | PIK3CD (0.35) | KCNH2SCN5ASCN9APIK3CDCNR1 | |
| SCHEMBL30983862 | 0.88 | KCNH2 (0.33) | KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31269258 | 0.88 | HRH4 (0.36) | KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31268817 | 0.88 | KCNH2 (0.38) | KCNH2SCN5ASCN9APIK3CDCNR1 | |
| SCHEMBL31268930 | 0.88 | KCNH2 (0.34) | KCNH2SCN5ASCN9APIK3CDCNR1 | |
| SCHEMBL31269054 | 0.87 | KCNH2 (0.34) | KCNH2SCN5ASCN9APIK3CDCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |